One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Breakthrough research into diabetes medications and stroke prevention Recent groundbreaking research has raised the possibility of a game-changing approach to stroke prevention. A study analyzing ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes compared with younger adults, according to findings from a systematic ...

Insulin, sulfonylureas, and TZDs are diabetes medications that may cause weight gain. But some, like metformin, may have weight loss potential. Others may be neutral to any weight changes.